Videos

This interview with Andrew Alexis, MD, MPH, features some of the most notable highlights from his AAD 2025 talks on therapeutic and diagnostic pearls for skin of color.

Pongdee also discussed the changing treatment landscape for indolent systemic mastocytosis and questions that will need to be answered in the field.

Bernstein also discussed other unmet needs in the field and how his center is working to address them.

In this interview with Christopher Bunick, MD, PhD, at AAD 2025, he discusses his update given in a presentation regarding acne and rosacea treatments.

Lipworth shared findings from 2 studies that he presented data from at the AAAAI/WAO Joint Congress.

This interview features a discussion with Christopher Bunick, MD, PhD, regarding recent controversies in acne and rosacea related to benzene and benzoyl peroxide.

Mostaghimi highlights the major takeaways from his talk on alopecia areata therapies, the contents of which were presented at AAD 2025.

Cianferoni discusses how pollen food allergy syndrome contributes to eosinophilic esophagitis (EoE) and potential management strategies.

At AAAAI 2025, Cianferoni described molecular mechanisms of pollen food allergy syndrome.

In this interview at AAD 2025, Bhutani highlights several points of consideration for clinicians treating patients who are pregnant and suffering from alopecia areata.

This interview at the Skin of Color Society (SOCS) Scientific Symposium features Elbuluk describing her plans as newly-elected president of SOCS.

Crystal Aguh, MD, discusses a study from AAD 2025 examining HbA1c levels and outcomes in CCCA.

This interview with Chovatiya highlights his portion of the ‘Skin of Color’ talk at the American Academy of Dermatology conference.

This interview with Snyder features a discussion on recent findings on remibrutinib among patients with chronic spontaneous urticaria, also known as CSU.

Robert Bissonnette, MD, discusses data from the ICONIC-LEAD trial and the potential role of icotrokinra in plaque psoriasis.

In this interview at AAD 2025, Craiglow speaks on her team’s late-breaking findings on baricitinib among adolescents with severe alopecia areata.

Stein Gold highlights her team's findings on tapinarof cream (Vtama) 1% from the 48-week ADORING 3 extension for those aged 2 to 17 with atopic dermatitis.

This AAD 2025 interview features a discussion with Sonja Ständer, MD, new phase 3 findings from OLYMPIA 1 and 2 on nemolizumab in patients with prurigo nodularis.

In this segment of Silverberg’s interview, she highlights providing anticipatory guidance for parents of children with molluscum as well as treatment options.

HCPLive spoke with Anagnostou at AAAAI on how to determine what food allergy treatment patients should undergo.

Chambliss and colleagues found a 1% increase in asthma-related emergency department visits per unit of distance to semiconductor fabrication plants.

At AAAAI, Golden discussed when to test for insect sting allergies, the role of venom immunotherapy, and the potential impact of epinephrine nasal spray.

In this interview at AAD 2025, Silverberg discusses important facts for dermatologists to know in the management of molluscum contagiosum.

At AAAAI 2025, David Golden, MD, discussed when to test for insect sting allergies, the role of mast cell disorders, and updated guidelines for all ages.

Eapen discussed her research into analyzing the cord blood methylome for markers that predict atopic dermatitis risk at the AAAAI/WAO Joint Congress.

In this interview, Aguh answers several key questions about the efforts of the Skin of Color Society and improving diversity in clinical research.

In part 2 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss strategies to address the CKD crisis.

HCPLive spoke with Golden at AAAAI on the pitfalls of diagnosing all patients with insect stings for insect sting allergies.